ER, PR and HER-2 discordances between primary and recurrent cancer and their impact on survival of breast cancer patient
10.13315/j.cnki.cjcep.2019.03.004
- VernacularTitle:乳腺癌原发肿瘤和复发肿瘤间ER、PR和HER-2表达不一致及其对患者生存的影响
- Author:
Yu-Feng YANG
1
;
Jian-Zhong YU
;
Si-Yuan LIN
;
Li-Hua ZHANG
;
Mei YANG
Author Information
1. 广东省东莞市第三人民医院病理科
- Keywords:
breast neoplasm;
hormone receptor;
HER-2;
discordance;
survival
- From:
Chinese Journal of Clinical and Experimental Pathology
2019;35(3):268-273
- CountryChina
- Language:Chinese
-
Abstract:
Purpose To assess the frequency of discordances in ER, PR and HER-2 status between primary and recurrent cancer and the impact of the discordance on breast cancer patient survival. Method Immunohistochemistry and/or fluorescent in situ hybridization was used to evaluate ER, PR and HER-2 status of primary and recurrent cancer in 62 breast cancer patients. The correlation between discordances in ER, PR and HER-2 receptors and clinicopathologic characteristics and patient survival was analyzed. Results Among 62 patients with breast recurrent cancer, discordance rate for ER, PR, and HER-2 was found in 6 (9.7％), 9 (14.5％) and 3 (4.8％) patients, respectively. During the follow-up period the ER-discordant cases had a poorer overall survival (median 29 months vs 44 months, P=0.021) and post-recurrence survival (median 6 months vs 15 months, P=0.027), compared with the concordant cases. No impact on overall survival or post-recurrence survival was observed for PR and HER-2 discordance when compared with the respective concordant cases (P> 0.05 for all).Conclusion Our results demonstrate an evident change regarding ER, PR and HER-2 between breast primary and recurrent cancer, and the ER unstable status in breast cancer suggust a worse prognosis.
